EVMN
NYSE · Biotechnology
Evommune Inc
$9.65
+0.28 (+2.99%)
Financial Highlights (FY 2026)
Revenue
14.06M
Net Income
-74,504,422
Gross Margin
—
Profit Margin
-529.8%
Rev Growth
—
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 42.8% | 42.8% | 42.8% |
| Operating Margin | -623.6% | -23.9% | -25.5% | -21.7% |
| Profit Margin | -529.8% | -21.4% | -26.9% | -27.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 14.06M | 78.02M | 75.69M | 85.24M |
| Gross Profit | — | 33.42M | 32.42M | 36.51M |
| Operating Income | -87,701,751 | -18,680,583 | -19,332,133 | -18,489,345 |
| Net Income | -74,504,422 | -16,723,517 | -20,379,208 | -23,619,828 |
| Gross Margin | — | 42.8% | 42.8% | 42.8% |
| Operating Margin | -623.6% | -23.9% | -25.5% | -21.7% |
| Profit Margin | -529.8% | -21.4% | -26.9% | -27.7% |
| Rev Growth | — | -7.7% | +21.3% | +18.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 444.7K | 82.29M | 83.85M | 90.36M |
| Total Equity | 171.04M | 243.06M | 274.02M | 233.46M |
| D/E Ratio | 0.00 | 0.34 | 0.31 | 0.39 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -86,202,173 | -28,105,243 | -27,281,553 | -29,215,509 |
| Free Cash Flow | — | -11,355,754 | -12,035,038 | -9,988,803 |